Cumulative annual coverage of meningococcal B vaccination in Australian general practice for three at-risk groups, 2014 to 2019

Costa, Juliana de Oliveira; Gianacas, Christopher; Beard, Frank; González‐Chica, David Alejandro; Chidwick, Kendal; Osman, Rawa; MacIntyre, C. Raina; Havard, Alys

doi:10.1080/21645515.2021.1923349

Cited by 4 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While data for vaccine uptake in at-risk individuals are limited, available data from the United States indicate relatively low coverage in at-risk populations, with uptake in individuals with complement deficiencies or with asplenia of 2.2% and 9.7%, respectively [ 150 , 151 ]. In Australia, between 2014 and 2019 the reported MenB vaccine coverage in adults > 50 years with at-risk medical comorbidities ranged from 12% to 14%, and was lower in those with lower socioeconomic status [ 152 ]. Efforts to increase vaccine uptake in at-risk adults where MenB immunisation is recommended should be a priority.…”

Section: Towards a Broader Adult Menb Vaccination Approachmentioning

confidence: 99%

Meningococcal B Immunisation in Adults and Potential Broader Immunisation Strategies: A Narrative Review

et al. 2023

View full text Add to dashboard Cite

Recombinant vaccines against invasive meningococcal disease due to Neisseria meningitidis serogroup B (MenB) have shown substantial impact in reducing MenB disease in targeted populations. 4CMenB targets four key N. meningitidis protein antigens; human factor H binding protein (fHbp), Neisserial heparin binding antigen (NHBA), Neisseria adhesin A (NadA) and the porin A protein (PorA P1.4), with one or more of these expressed by most pathogenic MenB strains, while MenB-FHbp targets two distinct fHbp variants. While many countries recommend MenB immunisation in adults considered at high risk due to underlying medical conditions or immunosuppression, there are no recommendations for routine use in the general adult population. We reviewed the burden of MenB in adults, where, while incidence rates remain low (and far lower than in young children < 5 years of age at greatest risk), a substantial proportion of MenB cases (20% or more) is now observed in the adult population; evident in Europe, Australia, and in the United States. We also reviewed immunogenicity data in adults from clinical studies conducted during MenB vaccine development and subsequent post-licensure studies. A 2-dose schedule of 4CMenB generates hSBA titres ≥ 1:4 towards all four key vaccine target antigens in up to 98–100% of subjects. For MenB-FHbp, a ≥ fourfold rise in hSBA titres against the four primary representative test strains was observed in 70–95% of recipients following a 3-dose schedule. While this suggests potential benefits for MenB immunisation if used in adult populations, data are limited (especially for adults > 50 years) and key aspects relating to duration of protection remain unclear. Although a broader adult MenB immunisation policy could provide greater protection of the adult population, additional data are required to support policy decision-making. Graphical Abstract

show abstract

Section: Towards a Broader Adult Menb Vaccination Approachmentioning

confidence: 99%

Meningococcal B Immunisation in Adults and Potential Broader Immunisation Strategies: A Narrative Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“… 145 Another US study found that, among people living with HIV, 16.3% received a MenACWY vaccine dose in the two years after diagnosis in 2019–2022. 146 In Australia, MenB vaccination coverage for people medically at risk of IMD was 12.1% in 2019, 147 and in Norway, two doses of MenACWY vaccine and MenB vaccine were received by, respectively, 4.2% and 8.0% of splenectomized patients up to 2020. 148 …”

Section: The Need For Improved Access To Menb Vaccination Among All A...mentioning

confidence: 99%

4CMenB journey to the 10-year anniversary and beyond

Abitbol,

Martinón-Torres,

Taha

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…Over the past decade, these data have been used by academics and NPS MedicineWise to inform industry and government agencies about primary care and post-market surveillance of medicines, informing policy and supporting quality improvement activities in general practice [15]. There are numerous reports and over 40 peer reviewed publications to date based on MedicineInsight data including studies investigating Australian opioid use [16,17], vaccination [18][19][20], and the management of chronic hepatitis C in general practice [21,22].…”

Section: Introductionmentioning

confidence: 99%

Evaluating the accuracy of data extracted from electronic health records into MedicineInsight, a national Australian general practice database

Daniels

Havard

Myton

et al. 2022

IJPDS

Self Cite

View full text Add to dashboard Cite

IntroductionMedicineInsight is a database containing de-identified electronic health records (EHRs) from over 700 Australian general practices. Previous research validated algorithms used to derive medical condition flags in MedicineInsight, but the accuracy of data fields following EHR extractions from clinical practices and data warehouse transformation processes have not been formally validated. ObjectivesTo examine the accuracy of the extraction and transformation of EHR fields for selected demographics, observations, diagnoses, prescriptions, and tests into MedicineInsight. MethodsWe benchmarked MedicineInsight values against those recorded in original EHRs. Forty-six general practices contributing data to MedicineInsight met our eligibility criteria, eight were randomly selected, and four agreed to participate. We randomly selected 200 patients ≥ 18 years of age within each participating practice from MedicineInsight. Trained staff reviewed the original EHRs for the selected patients and recorded data from the relevant fields. We calculated the percentage of agreement (POA) between MedicineInsight and EHR data for all fields; Cohen's Kappa for categorical and intra-class correlation (ICC) for continuous measures; and sensitivity, specificity, and positive and negative predictive values (PPV/NPV) for diagnoses. ResultsA total of 796 patients were included in our analysis. All demographic characteristics, observations, diagnoses, prescriptions and random pathology test results had excellent (> 90%) POA, Kappa, and ICC. POA for most recent pathology/imaging test was moderate (81%, [95% CI: 78% to 84%]). Sensitivity, specificity, PPV, and NPV were excellent (> 90%) for all but one of the examined diagnoses which had a poor PPV. ConclusionsOverall, our study shows good agreement between the majority of MedicineInsight data and those from original EHRs, suggesting MedicineInsight data extraction and warehousing procedures accurately conserve the data in these key fields. Discrepancies between test data may have arisen due to how data from pathology, radiology and other imaging providers are stored in EHRs and MedicineInsight and this requires further investigation.

show abstract

Cumulative annual coverage of meningococcal B vaccination in Australian general practice for three at-risk groups, 2014 to 2019

Cited by 4 publications

References 32 publications

Meningococcal B Immunisation in Adults and Potential Broader Immunisation Strategies: A Narrative Review

Meningococcal B Immunisation in Adults and Potential Broader Immunisation Strategies: A Narrative Review

4CMenB journey to the 10-year anniversary and beyond

Evaluating the accuracy of data extracted from electronic health records into MedicineInsight, a national Australian general practice database

Contact Info

Product

Resources

About